Japan's superior alternative to Paxlovid called Xocova, finally available in US

8 hours ago

XOCOVA (ensitrelvir) is now available by prescription in the U.S. for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 and older.
In a Phase 3 clinical trial (SCORPIO-PEP), XOCOVA reduced the risk of symptomatic COVID-19 by 67% following exposure to an infected individual compared to placebo.
The medication is taken once daily for five days: three 125 mg tablets on day one, then one 125 mg tablet on days two to five, starting within 72 hours of exposure.
XOCOVA's availability comes ahead of an anticipated summer surge in COVID-19 cases, as indicated by rising SARS-CoV-2 levels in wastewater and CDC modeling.
Experts emphasize the importance of having XOCOVA on hand for quick action after exposure, especially for older adults and those with high-risk conditions.

The situation in the Netherlands is currently good, but the exact reasons remain unclear.
COVID-19 infections primarily occur indoors; experts advise avoiding crowded indoor spaces.
Vaccine development is progressing well, with 150 candidates in development and promising results in animal trials.

COVID-19 is far worse than seasonal flu, with significant mortality and strain on healthcare systems.
Social distancing, hand washing, and coughing hygiene are effective measures to slow the spread.
Warmer weather may slightly reduce transmission but strong measures are still necessary.

The sharp rise in COVID-19 cases is primarily among the 10-29 age group, while hospitalizations and deaths are still declining.
Indoor events are risky, with 180 infections traced to a single nightclub despite testing requirements; caution is advised.
Vaccines are effective against severe illness from the Delta variant but do not prevent all infections; vaccinated individuals can still transmit the virus.

All vaccines offer >90% protection against severe COVID-19, including variants.
Vaccine-induced immunity is stronger and longer-lasting than natural infection.
Mixing vaccines (e.g., AstraZeneca with Pfizer) is safe and effective, boosting antibodies.

Current situation unclear: cases rising in many countries, but vaccine efficacy against severe disease remains high.
Potential double epidemic with flu, but flu cases currently low; vaccination can reduce unvaccinated by 25% in communities with 80% coverage.
Ventilation and air purifiers (including simple filters) are effective in reducing transmission.

Hasty Briefsbeta